Form 4: Sionna Therapeutics Director Bruce Booth Reports Stock Option Grant

Sionna Therapeutics, Inc. Director Bruce Booth has reported the grant of 19,959 non-qualified stock options with an exercise price of $16.99, vesting by June 2026.

Summary

• Bruce Booth, a Director of Sionna Therapeutics, Inc. (SION), was granted 19,959 non-qualified stock options.
• The options have an exercise price of $16.99 per share.
• The transaction date for the grant was June 12, 2025.
• The options vest in full upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on Mr. Booth's continued service.
• The options expire on June 11, 2035.
• Mr. Booth disclaims beneficial ownership for Section 16 purposes, as proceeds from any sale of shares upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing reporting an equity grant to a director, which is a routine and expected disclosure with no inherently positive or negative implications for company performance or financial health.

Positives

• The grant of stock options to Director Bruce Booth aligns his interests with those of shareholders, potentially incentivizing long-term performance and value creation.

Risks

• The reporting person disclaims beneficial ownership of the securities for Section 16 purposes, as proceeds from any sale upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, except to the extent of his pecuniary interest therein, if any.

Future Outlook

The stock options granted to Director Bruce Booth are set to vest in full upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on his continued service.

Industry Context

This filing is a standard disclosure of an insider equity transaction, common across all industries, and does not provide specific industry-wide insights or trends beyond the company's internal compensation practices.

Comparison to Industry Standards

• N/A

Related Party Transactions

• Proceeds from any sale of shares of common stock issued upon exercise of the option will be transferred to Atlas Venture Life Science Advisors, LLC, indicating a potential related party arrangement given the reporting person's likely affiliation.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns management incentives with shareholder interests, potentially encouraging long-term value creation.

Next Steps

• The stock options will vest in full upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service.

Key Dates

Keywords

Sionna Therapeutics, SION, SEC Form 4, stock option grant, insider transaction, director compensation, equity compensation